🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

As reported by Becca Carballo of Houston Chronicle – #OBX115 received IND clearance, and clinical trials in #metastaticmelanoma will begin soon. The research teams hope they have found a technique that is more effective without harsh side effects: bit.ly/3dskmkP

Obsidian Therapeutics #CSO, Jan ter Meulen, Ph.D., will be attending Citi 17th Annual BioPharma Conference 2022 and participating in a panel on #celltherapy on September 7, at 3:30 p.m. ET, Boston. Learn more: obsidiantx.com/news-releases/…

#Summit – Our #team will be attending the Jefferies Cell & Genetic Medicine Summit happening in NYC September 29 - 30. Our management team will also be participating in 1x1 #investormeetings during the event.

Our #CEO, Paul Wotton, spoke with @MattPillar of the #BusinessofBiotech #podcast about Obsidian’s path to FDA clearance of the IND application for #OBX115 this past summer. Listen BioProcess Online: bioprocessonline.com/doc/ind-for-ti…

Obsidian’s Director of Process Development, Katie Aron, Ph.D., will be speaking today at the Process Development for #Cell Therapy Summit at 2:30 p.m. ET in Woburn, MA. Learn more: obsidiantx.com/news-releases/…

Obsidian’s Shyam Subramanian, Ph.D., #CTO, will be speaking today at the Process Development for #Cell Therapy Summit at 3:00 pm ET in Woburn, MA. Learn more: obsidiantx.com/news-releases/…

Jan ter Meulen, Ph.D., #CSO at Obsidian, will be participating in a panel discussion at the Neoantigen Based Therapies Summit, today at 2 PM ET on strategies to counter the TME. #IL2 #IL15 #celltherapy #cancer

Our #CSO, Jan Ter Meulen, Ph.D., will be presenting at the TIL Therapies Summit, today at 12:30 PM ET. He will discuss our #TILtherapy candidate #OXB115 in a presentation titled “Engineering an IL2-Free, Potent & Persistent TIL with Regulated Membrane-Bound IL15.” #IL2 #IL15

Today we announced the extension of our multi-year strategic collaboration with @BMSnews for the discovery and development of novel, regulated cell therapies that utilize our cytoDRiVE technology! Read more: obsidiantx.com/news-releases/… #CGT #celltherapy

#InvestorConference - Our management team will be attending the SVB Leerink Biopharma Private Company Connect virtually October 26 –27.

Today we announced that we will be presenting #preclinical data highlighting our recent #cytoDRiVE platform and pipeline advances during the poster sessions at #SITC22 Society for Immunotherapy of Cancer. For more details on the presentations and abstract summaries: obsidiantx.com/news-releases/…

Our team will present the poster “Enhancers of innate and adaptive immunity combine with membrane-bound IL15 to increase the efficacy of (TIL) therapy for tumors with immunosuppressive microenvironments” today at Society for Immunotherapy of Cancer. #SITC22 Learn more: bit.ly/3A3zUns

Today our poster “Pharmacologically-controlled expression of membrane-bound IL-12 results in T-cell therapy with enhanced potency in preclinical solid tumor models” will be presented by our team at #SITC. Learn more about all our posters at Society for Immunotherapy of Cancer: obsidiantx.com/news-releases/…

#SITC22 – Our team will be presenting the poster “Digital spatial profiling and antigen-dependent phenotypic analysis of IL15-engineered tumor-infiltrating lymphocytes (cytoTIL15™ therapy) in an allogeneic melanoma PDX model” today. #CheckItOut: obsidiantx.com/news-releases/…

.FierceBiotech covered our partnership extension with Bristol Myers Squibb. The collaboration extension provides the exclusive option for BMS to in-license rights for #celltherapy candidates utilizing our #cytoDRiVE technology to control the expression of CD40L. bit.ly/3DQrqT2

Our partnership with Vertex Pharmaceuticals was featured in @nature as one of the top 20 strategic alliance deals in the #celltherapy and #genetherapy space. The collaboration leverages our cytoDRiVE technology to discover controllable genetic therapies. Read more: bit.ly/3FgkAqQ

Today at 3:40 pm, Jan ter Meulen, M.D., Ph.D., CSO, will present “Armoring TIL for Increased Persistence, Potency and Impact on the Tumor Microenvironment” during the IO360° Summit The Conference Forum. Check out the full agenda at theconferenceforum.org/conferences/im…